What Individual Investors Don't See Until It's Too Late: The Arithmetic of a Headline Deal
On 30 July 2026, Korea's Financial Supervisory Service published its comprehensive plan to overhaul pharmaceutical and biotech disclosure. The reform is unusually specific about a single number: the total value of a technology-transfer agreement. Under the new framework, a licensing deal can no longer be disclosed as one figure. Companies must break it into four lines — upfront payment, development milestones, approval and sales milestones, and royalties — and state the payment condition and character of each. The FSS was explicit about why: because only the total was published, milestones and royalties, which are payable solely on the satisfaction of conditions, were being read as amounts already secured at signing. The reform reaches further back than that. At the IPO stage, the assumptions behind a valuation must now be set out in four standardised categories: expected market size, probability of clinical success, approval and review risk, and development period and cost. Expe...